Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02919449 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab
A Phase 1 study, sponsored by Vyriad.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02919449 is a Phase 1 study that was terminated before completion, run by Vyriad. The registered enrollment target is 2 participants.
The verdict
NCT02919449, a Phase 1 study, was terminated before completion, sponsored by Vyriad.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of attenuated Measles virus (MV-NIS) combined with Atezolizumab in patients with recurrent and metastatic NSCLC.
Interventions
- BIOLOGICAL Atezolizumab
- BIOLOGICAL MV-NIS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-08-03 |
| Est. Completion | 2018-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02919449
The ClinicalTrials.gov registry entry for NCT02919449 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vyriad, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT02919449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02919449 about?
NCT02919449 is a clinical study titled "Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab". This a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of attenuated Measles virus (MV-NIS) combined with Atezolizumab in patients with recurrent and metastatic NSCLC.
What is the current status of trial NCT02919449?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2017-08-03. Estimated completion is 2018-01-19.
What interventions are being tested in trial NCT02919449?
The interventions under investigation include: Atezolizumab (BIOLOGICAL), MV-NIS (BIOLOGICAL).
Who is sponsoring clinical trial NCT02919449?
This trial is sponsored by Vyriad, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.